

Prescribing and Formulary Panel

Minutes of a meeting held at 5pm Tuesday September 13th 2022 Oak MDT Room

Present

Geraldine O’Riordan, Prescribing Advisor and Chair (GOR)

Douglas Wilson, Queens Road Medical Practice (DW)

Tom Saunders, Medical Specialist Group (TS)

Peter Gomes, Medical Specialist Group (PG)

Andrew Ward, PEH Pharmacy Manager (AW)

Mike McCarthy, Healthcare Group

Paul Williams, Island Health Medical Practice

Absent

Nikki Brink

Draft Minutes

The Draft minutes of the August 2022 meeting were approved.

- **New Drugs**

V5 COVID-19 Treatment and preventative agents

This document, previously approved, was updated to include one new preventative agent, Evusheld^R (Update: UK Marketing authorisation obtained September 2022). The new product was recommended for approval for use in accordance with local or National Guidance and the other caveats in the paper. The paper and the August minutes noted the issue pharmacy capacity, which is limited. Primary Care was kindly requested, at the August meeting, to avoid prescribing Paxlovid^R at weekends. GOR said that the NNTs for prevention of 1 hospitalisation was 18 when treatment was started within 3 days of a positive test result and 19 when started within 5 days. Taking the CI into account it is highly likely that there is no clinically significant difference between treatment within 3 days and treatment within 5 days. AW advised that Jersey has now involved one community pharmacy in dispensing of Paxlovid^R on behalf of the hospital. After a discussion, it was agreed to approve the paper, with the pharmacy teams to agree dispensing arrangements of Paxlovid^R in due course.

- **Minor and/or cost-neutral additions or changes to the Prescribing List or the Hospital Formulary and cost implications**

The following were discussed and approved

1. Liraglutide entry: change to “Victoza^R” only, the TA for the identical liraglutide product “Saxenda^R” for weight management is not yet implemented. Prescribers are asked to only prescribe Victoza according to the NICE NG for people with diabetes and not for weight management in people who are not diabetic.
Dimethyl fumarate capsules 120mg, 240 mg: Remove reference to purchasing by PEH Pharmacy only.
2. Nabilone: Recommending that its use be restricted to its licensed indication, chronic intractable nausea and vomiting associated with chemotherapy, so for Oncology only and for PEH dispensing only.
3. Abacivir 600mg/Lamivudine 300mg generic combination to be added to list.
4. Maviret^R 50mg/20mg granules in sachets, requested by GOSH for a child with Hep C who is unable to swallow tablets. Treatment is to be in accordance with the SPC and national guidelines, so for 8 weeks, and the product will be for PEH pharmacy dispensing only. GOR to liaise with the UK hospital re cost and to consider alternative ways of dispensing.
UPDATE: The price quote was found to contain an error, making this product now available to Guernsey at the significantly discounted NHSE contract price.

- **New NICE TAs** : noted

DW commented that he found separate papers for oncology and non-oncology drugs very helpful.

- **Environmentally friendly inhalers**

After a discussion this was approved.

Action: GOR

- **Short burst home oxygen therapy in cluster headache:**
-

The draft guidelines were discussed. After a discussion it was agreed that Consultant Neurology opinion would be sought on how Primary Care would initiate this treatment in the safest and most cost-effective way.

Action : GOR

- **MDS boxes in the community**

Due to staff absences preparation of the updated policy has been delayed.

- **DOAC Prescribing guidelines**

Verbal update on apixaban patent expiry : still no change in UK Drug Tariff cost.

- **Black Triangle Drugs:** no update this month. All new NICE TAs are black triangle drugs.

- **New NMPs:** none

- **Dates of next meetings**

Tuesday October 11th 5pm Oak MDT Room

Tuesday November 15th 5pm Oak MDT room (**NB note change of date**)